Latest News

Certifying pharmacy technicians to administer immunizations streamlines workflow, combats vaccine misinformation, and positions pharmacies to fill a coming gap in physician access.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction–associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

A lesser-known viral protein may drive both the hyperinflammation and vascular damage seen in severe and long COVID-19.

The FDA granted Fast Track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Night shift and insomnia may triple long-COVID risk; learn how chronic insomnia and long-COVID links affect health workers and prevention.

The FDA granted fast track designation to safusidenib, an investigational oral IDH1 inhibitor that produced durable responses in a phase 2 study of patients with treatment-naive grade 2 IDH1-mutant glioma.

Given the growing market availability and current underutilization of biosimilars, pharmacists must possess a comprehensive understanding of these agents to effectively advocate for their adoption.

Cardiomyopathy, hepatitis B, breast cancer, hypertension, and myeloma decisions land in the FDA's final-quarter queue.

Its targeted PDE4 mechanism, favorable safety profile, and supportive pediatric data make it a meaningful long-term treatment addition.

What began as a question about duplicative therapy ultimately led to a patient-specific intervention, the development of a tool for communicating recommendations, and a resource now available to pharmacists.

Gastric emptying delay and glucose-dependent insulin secretion make dietary counseling essential in every GLP-1 receptor agonist encounter.

Following community reports of more than 400 cancer cases in Keyport and Union Beach, New Jersey officials are expanding environmental sampling near a former landfill.

Genglycos wins accelerated approval to cut daily cornstarch reliance in patients aged 8 and older with the rare metabolic disorder.

As artificial intelligence–based tools grow in popularity, helping patients know when to use digital tools and when to ask a clinician is essential.

As case counts rise in the current outbreak, pharmacists must be prepared to counsel patients regarding management, including pediatric patients who require unique considerations.

Decode carcinogens: IARC hazard vs risk, what "possibly" means, and how pharmacists ease aspartame, meat, and phone fears.

Garetosmab-grts cut new heterotopic ossification lesions by 90% or more at 56 weeks in the phase 3 OPTIMA trial.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival over pembrolizumab alone.

Findings published in Lancet Child & Adolescent Health arrive as a new US executive order shifts rotavirus vaccination to shared clinical decision-making.